Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/852,447external-prioritypatent/US5968961A/en
Priority claimed from US08/887,810external-prioritypatent/US5856348A/en
Application filed by Romark Lab LcfiledCriticalRomark Lab Lc
Publication of CU22990A3publicationCriticalpatent/CU22990A3/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a una composición farmaceútica que contiene como agente activo por lo menos un compuesto seleccionado del grupo integrado la fórmula (I) ESPACIO PARA FÓRMULA y la fórmula (II) ESPACIO PARA FÓRMULA El agente activo tiene preferentemente la forma de partículas con un tamano de partícula menor que 200um y un tamano medio de partícula mayor que 10um. De manera preferente, las composiciones farmaceúticas están estabilizadas con por lo menos un ácido farmaceúticamente aceptable. Las composiciones farmaceúticas de la presente invención son útiles para el tratamiento de infecciones oportunistas en personas con el sistema inmune comprometido o suprimido, así como en el tratamiento de infecciones por tremátodos.The present invention relates to a pharmaceutical composition containing as active agent at least one compound selected from the integrated group the formula (I) FORMULA SPACE and the formula (II) FORMULA SPACE The active agent preferably has the form of particles with a particle size less than 200um and an average particle size greater than 10um. Preferably, the pharmaceutical compositions are stabilized with at least one pharmaceutically acceptable acid. The pharmaceutical compositions of the present invention are useful for the treatment of opportunistic infections in people with the compromised or suppressed immune system, as well as in the treatment of trematode infections.
CU1999179A1997-05-071999-10-29
PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITAZOXADINE
CU22990A3
(en)
PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
Triggered Response and Triggered Response Barrier Compositions, device for the triggered release of one or more active ingredients to an aqueous system, and process for triggering the release of one or more active ingredients to an aqueous system
Compound, pharmaceutical composition, and processes to inhibit the release of luteinizing hormone (lh) in a mammal in need of such treatment and to prepare a compound
FORM OF FANCICLOVIR, PROCEDURE FOR PREPARING IT, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS AND THE USE OF SUCH FORM -FANCICLOVIR MONOIDRATE.